Gossamer Bio Ownership

GOSS Stock  USD 0.70  0.01  1.41%   
Gossamer Bio has a total of 226.6 Million outstanding shares. The majority of Gossamer Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Gossamer Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Gossamer Bio. Please pay attention to any change in the institutional holdings of Gossamer Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2017-12-31
Previous Quarter
238.5 M
Current Value
226.3 M
Avarage Shares Outstanding
91.2 M
Quarterly Volatility
66.1 M
 
Covid
Some institutional investors establish a significant position in stocks such as Gossamer Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Gossamer Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Paid And Capex Coverage Ratio is likely to gain to -430.17 in 2024. Common Stock Shares Outstanding is likely to gain to about 160.3 M in 2024, whereas Net Loss is likely to drop (216.8 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gossamer Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Gossamer Stock please use our How to Invest in Gossamer Bio guide.

Gossamer Stock Ownership Analysis

About 77.0% of the company shares are owned by institutional investors. The book value of Gossamer Bio was currently reported as 0.24. The company recorded a loss per share of 0.25. Gossamer Bio had not issued any dividends in recent years. Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California. Gossamer Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 185 people. To learn more about Gossamer Bio call the company at 858 684 1300 or check out https://www.gossamerbio.com.

Gossamer Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Gossamer Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Gossamer Bio backward and forwards among themselves. Gossamer Bio's institutional investor refers to the entity that pools money to purchase Gossamer Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Eversept Partners, Llc2024-09-30
M
Hillhouse Capital Advisors, Ltd.2024-09-30
M
Monaco Asset Management2024-09-30
3.9 M
Deutsche Bank Ag2024-06-30
3.8 M
Opaleye Management Inc2024-09-30
3.7 M
Junked Platinum Investment Management Ltd2024-09-30
3.5 M
Marshall Wace Asset Management Ltd2024-09-30
3.5 M
Ci Private Wealth Llc2024-09-30
3.4 M
Rock Springs Capital Management Lp2024-09-30
3.3 M
Nea Management Company, Llc2024-09-30
18.1 M
Vanguard Group Inc2024-09-30
11.8 M
Note, although Gossamer Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Gossamer Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Gossamer Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Gossamer Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Gossamer Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Gossamer Bio Outstanding Bonds

Gossamer Bio issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Gossamer Bio uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Gossamer bonds can be classified according to their maturity, which is the date when Gossamer Bio has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Gossamer Stock Analysis

When running Gossamer Bio's price analysis, check to measure Gossamer Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gossamer Bio is operating at the current time. Most of Gossamer Bio's value examination focuses on studying past and present price action to predict the probability of Gossamer Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gossamer Bio's price. Additionally, you may evaluate how the addition of Gossamer Bio to your portfolios can decrease your overall portfolio volatility.